Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update, outlining plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. CL-741 targets EGFR-mutated lung cancer and other cancers, complementing Kairos’ existing portfolio of ENV-105, KROS-201, KROS-102 and ENV-205.
The company expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. Kairos also secured more than $8 million in non-dilutive funding to support its preclinical and clinical programs. For details, see the full press release at https://ibn.fm/WuBOf.
Kairos Pharma, based in Los Angeles, California, focuses on oncology therapeutics using structural biology to overcome drug resistance and immune suppression. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein driving resistance and disease relapse. ENV-105 aims to restore effectiveness of standard therapies across multiple cancer types. It is currently in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the press release date, ENV-105 has not been approved as safe or effective by the FDA or any comparable foreign regulator.
The acquisition of CL-741 is a strategic move to broaden Kairos’ pipeline with an oral targeted therapy. CL-741 is a c-MET kinase inhibitor designed for cancers with MET amplification or overexpression, often associated with resistance to EGFR inhibitors. This addition could provide a complementary approach to ENV-105, which targets CD105-mediated resistance. The company’s ability to secure non-dilutive funding, including grants and partnerships, supports the advancement of multiple programs without shareholder dilution.
Investors can stay updated on Kairos Pharma developments through the company’s newsroom at https://ibn.fm/KAPA. The mid-year update reflects Kairos’ commitment to addressing unmet medical needs in oncology, leveraging its proprietary platform to develop therapies that could improve outcomes for patients with resistant cancers.
